Research archive · This publication is preserved from the LEMMO Cancer Care library. Findings are specific to the study design and population and may not reflect current clinical practice.
Ned Tijdschr Geneeskd. 1999 Jan 9;143(2):80-4.
van der Zee J, van Rhoon GC, Wijnmaalen AJ, Koper PC, van Putten WL.
Source
Academisch Ziekenhuis Rotterdam-Daniel den Hoed Kliniek.
Abstract
In the Daniel den Hoed Cancer Centre in Rotterdam, the Netherlands, patients with recurrent breast cancer within a previously irradiated area, are treated by application of hyperthermia in addition to reirradiation. In this development, the following issues are important: (a) the choice of an effective and tolerable reirradiation schedule; (b) the establishment of the limitations of the hyperthermia techniques available; (c) the finding that additional hyperthermia has to be applied to the total tissue volume at risk for tumour recurrence; (d) the assessment of the value of additional hyperthermia by a randomised study. With the reirradiation schedule of 8 x 4 Gy and the hyperthermia application technique at present available, local control is achieved in 76% of the patients for a median duration of 32 months. The probability of local control is related to tumour size. The treatment is tolerated well, with acceptable toxicity. In patients with recurrent breast cancer in a previously irradiated area, combined reirradiation and hyperthermia is very effective, well tolerated and little toxic.